

78. Stančík M, Mokáň M, Sádová I, et al. Úloha vaspínu v patogenéze koronární choroby srdce. *Vnitř Lék* 2015; 61: (Suppl. 2): 14–19.
79. Gonzalez CR, Caminos JE, Vazquez MJ, et al. Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue. *Journal of Physiology*. 2009; 587: 3741–3750.
80. Handisurya A, Riedl M, Vila G, et al. Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. *Obesity Surgery* 2010; 20: 198–203.
81. Cinar N, Gülçelik NE, Aydın K, et al. Serum vaspin levels in hypothyroid patients. *Eur J Endocrinol*. 2011; 165: 563–569.
82. Samal B, Sun Y, Stearns G, et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. *Mol and Cell Biol* 1994; 14: 1431–1437.
83. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. *J Immunol* 2007; 178: 1748–1758.
84. Tanaka M, Nozaki M, Fukuhara A, et al. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. *Biochem Biophys Res Commun* 2007; 359: 194–201.
85. Chu CH, Lee JK, Wang MC, et al. Change of visfatin, C-reactive protein concentrations, and insulin sensitivity in patients with hyperthyroidism. *Metabolism* 2008; 57: 1380–1383.
86. Han J, Zhang TO, Xiao WH, et al. Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism is partially relevant to a nonlinear regulation mechanism between visfatin and tri-iodothyronine with various concentrations. *Chin Med J* 2012; 125: 874–881.
87. MacLaren R, Cui W, Cianflone K. Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. *Diabetes Obes Metab* 2007; 9: 490–497.
88. Ozkaya M, Sahin M, Cakal E, et al. Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. *J Endocrinol Invest* 2009; 32: 435–439.
89. Caixàs A, Tirado R, Vendrell J, et al. Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters. *Clin Endocrinol (Oxf)* 2009; 71: 733–738.
90. Imrich R. Metabolické dôsledky chronického zápalu. In: Úvod do imunológie a patogenéza vybraných autoimunitných ochorení. Bratislava: Vydavateľstvo UK 2016, 33–34.
91. Smékal A, Václavík J, Stejskal D, et al. Je u mladých pacientů s infarktem myokardu možné vyšetřovat expresi adipokinů v leukocytech periferní krve? In: XXXII. dny mladých internistů. *Vnitř Lék* 2013; 59: 1P1–1P36.